3.17
0.02 (0.80%)
| Previous Close | 3.14 |
| Volume | 1,047,150 |
| Price / Sales | 9.81 |
| Price / Book | 1.53 |
| 52 Weeks Range |
| Profit Margin | -259.60% |
| Operating Margin (TTM) | -402.93% |
| Diluted EPS (TTM) | -1.48 |
| Quarterly Revenue Growth (YOY) | 138.20% |
| Total Debt/Equity (MRQ) | 32.99% |
| Current Ratio (MRQ) | 5.70 |
| Operating Cash Flow (TTM) | -80.32 M |
| Levered Free Cash Flow (TTM) | -53.06 M |
| Return on Assets (TTM) | -20.30% |
| Return on Equity (TTM) | -45.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | C4 Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.38 |
|
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 9.79% |
| % Held by Institutions | 91.87% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ADAMS KENDRA | - | 3.39 | -2,775 | -9,407 |
| Aggregate Net Quantity | -2,775 | |||
| Aggregate Net Value ($) | -9,407 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 3.39 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ADAMS KENDRA | Officer | 18 Sep 2026 | Disposed (-) | 2,775 | 3.39 | 9,407 |
| ADAMS KENDRA | Officer | 18 Sep 2026 | Option execute | 6,250 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |